Stockscreener 앱 받기
12.82
2.44%
-0.32
전일 마감가:
$13.14
열려 있는:
$13.36
하루 거래량:
390.19K
Relative Volume:
1.58
시가총액:
$476.22M
수익:
$11.88M
순이익/손실:
$-162.08M
주가수익비율:
-1.0269
EPS:
-12.484
순현금흐름:
$-156.43M
1주 성능:
+8.28%
1개월 성능:
-9.65%
6개월 성능:
-50.12%
1년 성능:
+0.23%
1일 변동 폭
$12.62
$13.36
1주일 범위
$11.82
$13.81
52주 변동 폭
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
명칭
Crescent Biopharma Inc
전화
617-430-5595
주소
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
12.82 | 476.22M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-06 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2026-06-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2026-01-28 | 개시 | Piper Sandler | Overweight |
| 2026-01-21 | 개시 | Guggenheim | Buy |
| 2025-08-25 | 개시 | Jefferies | Buy |
| 2025-08-11 | 개시 | H.C. Wainwright | Buy |
| 2025-07-14 | 개시 | Wedbush | Outperform |
| 2025-06-25 | 개시 | Stifel | Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2024-07-26 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-22 | 개시 | CapitalOne | Overweight |
| 2021-11-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-05 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-12-18 | 개시 | H.C. Wainwright | Buy |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-07-26 | 개시 | SunTrust | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-17 | 재확인 | Stifel | Buy |
모두보기
Crescent Biopharma Inc 주식(CBIO)의 최신 뉴스
H.C. Wainwright reiterates Crescent Biopharma stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Crescent Biopharma stock rating at buy By Investing.com - Investing.com Canada
Stifel reiterates Crescent Biopharma stock rating on pipeline progress By Investing.com - Investing.com South Africa
Stifel reiterates Crescent Biopharma stock rating on pipeline progress - Investing.com
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering - Yahoo Finance
Crescent Biopharma Announces Grants of Inducement Awards - Yahoo Finance
Stifel reiterates Buy on Crescent Biopharma stock, $28 target - Investing.com
Crescent Biopharma stock rating upgraded to buy at H.C. Wainwright - Investing.com
Crescent Biopharma Announces FDA Clearance of IND for CR-002 and Plans Global Phase 1/2 APOLLO Trial in Advanced Solid Tumors - Quiver Quantitative
Crescent Biopharma Announces Grants of Inducement Awards - Yahoo Finance
Crescent Biopharma (Nasdaq:CBIO)Stock Analysis - Simply Wall Street
BetterLife Pharma Raises $100 Million in a Public Offering of Shares and Warrants - Yahoo Finance
Planned 804-share sale at Crescent Biopharma (Nasdaq: CBIO) - Stock Titan
Certain Warrants of Crescent Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
Certain Options of Crescent Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
CBIO: Major clinical milestones and global expansion set for 2027, with key data and partnerships advancing - TradingView
Crescent Biopharma at Cantor conference: global trial push By Investing.com - Investing.com Canada
Crescent Biopharma at Cantor conference: global trial push - Investing.com India
Crescent Biopharma at Cantor conference: global trial push - investing.com
Two employees receive options tied to 58,650 Crescent Biopharma shares - Stock Titan
Crescent Biopharma Announces Grants of Inducement Awards - Yahoo Finance
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsIV Contraction - vinanet.vn
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsTRIN Signal - siam.in
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsStatistical Arbitrage - dars.gov.et
Crescent Biopharma Announces September 2026 Investor Conference Presentations - quiverquant.com
Crescent Biopharma to Present at September Investor Conferences - GlobeNewswire
Crescent Biopharma to Present at September Investor Conferences - Yahoo Finance
Crescent Capital (CCAP) holder sells at about $10.50 under trading plan - Stock Titan
PMV Pharma Announces Proposed Public Offering of Securities - Yahoo Finance
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Balyasny Asset Management L.P. Expands Stake in Crescent Biophar - GuruFocus
Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 4.9%Should You Buy? - MarketBeat
Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Gap DownShould You Sell? - MarketBeat
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants - Yahoo Finance
Crescent Biopharma (CBIO) Shares Dip 2.86% as Stock Approaches Key $16 Support LevelDay Trade Opportunities - vinanet.vn
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
CBIO Q2 2026 Earnings: Narrower-Than-Expected Loss Buoys SharesRevenue Miss Report - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q3 EPS Forecast for Crescent Biopharma Lowered by Analyst - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewswire
CRESCENT BIOPHARMA, INC. SEC Filing (Aug 3, 2026) - Stock Titan
Perceptive Advisors LLC Lowers Stake in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (CBIO) Gets a Buy from Wedbush - The Globe and Mail
Crescent Biopharma Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Crescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003 - Quiver Quantitative
Crescent Biopharma: Q2 Earnings Snapshot - KING5.com
Crescent Biopharma Inc (CBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Crescent Biopharma Inc 주식 (CBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Joshua T Brumm | Officer |
Sep 18 '26 |
Proposed Sale |
17.18 |
9,013 |
154,843 |
0 |
| Jonathan McNeill | Officer |
Sep 18 '26 |
Proposed Sale |
17.18 |
4,415 |
75,850 |
0 |
| McNeill Jonathan | President and COO |
Sep 18 '26 |
Sale |
16.71 |
3,839 |
64,150 |
134,588 |
| Brumm Joshua T | Chief Executive Officer |
Sep 18 '26 |
Sale |
16.71 |
7,837 |
130,956 |
271,765 |
| Brumm Joshua T | Chief Executive Officer |
Sep 16 '26 |
Sale |
17.90 |
1,610 |
28,819 |
279,602 |
| McNeill Jonathan | President and COO |
Sep 16 '26 |
Sale |
17.90 |
731 |
13,085 |
138,427 |
| Jonathan McNeill | Officer |
Sep 16 '26 |
Proposed Sale |
18.80 |
804 |
15,115 |
0 |
| Joshua T Brumm | Officer |
Sep 16 '26 |
Proposed Sale |
18.80 |
1,771 |
33,295 |
0 |
| Pinkas Jan | Chief Scientific Officer |
Sep 16 '26 |
Sale |
17.90 |
658 |
11,778 |
21,581 |
| Im Ellie Eunkyung | Chief Medical Officer |
Sep 16 '26 |
Sale |
17.90 |
623 |
11,152 |
21,446 |
3.09%
0.72%
자본화:
|
볼륨(24시간):